Press Releases

LIQUID STABLE CLINICAL ENZYME CALIBRATION VERIFIERS FOR AMYLASE & LIPASE TESTING NOW AVAILABLE FROM VERICHEM

VERICHEM LABORATORIES now offers multi-level calibration verification materials for amylase and lipase activity as part of its liquid stable, ready-to-use Enzyme ER™ Verifier Kit.

Biotech lab TruDiagnostic and NADMED partner to launch novel NAD blood test in United States

NADMED has announced that TruDiagnostic partner to launch novel NAD blood test in the United States.

BioIVT to Highlight its Drug-Drug Interaction and ADME Research Expertise at the SOT Annual Meeting and ToxExpo

It will provide strategies to de-risk each stage of the R&D pipeline, with particular focus on regulatory drivers, investigatory objectives, and practical concerns that are relevant to toxicologists.

Clinion Launches Revolutionary AI-Powered Medical Coding Solution for Clinical Trials

[London, UK] - Clinion, a leading provider of eClinical solutions, has announced the launch of its new AI-powered medical coding solution. This innovative solution is designed to transform the medical coding process for clinical trials, offering a faster, more efficient, and more accurate way to code medical data. Medical coding is a critical component of clinical trials, as it enables researchers to accurately capture and analyze medical data. However, the process of medical coding can be time-consuming, error-prone, and costly, often leading to delays in the clinical trial process. Clinion's new AI Medical Coding is set to revolutionize the clinical trial process by leveraging the power of artificial intelligence to automate medical coding. The solution uses advanced machine learning algorithms to analyze medical data and assign the appropriate medical codes, significantly reducing the time and effort required for manual coding. The solution also provides real-time feedback to clinical trial teams, allowing them to make data-driven decisions more quickly and efficiently. With improved accuracy and speed, Clinion's medical coding solution enables clinical trial teams to deliver high-quality results and insights faster than ever before. "We are thrilled to launch AI Medical Coding, which we believe will transform the clinical trial process," said Manuj Vangipurapu, CEO of Clinion. "By harnessing the power of AI, we can provide clinical trial teams with a faster, more efficient, and more accurate way to code medical data. This will enable our customers to make data-driven decisions more quickly and effectively, ultimately accelerating the drug development process and bringing new treatments to patients faster." Clinion's medical coding solution is the latest addition to its suite of eClinical solutions, which include EDC, RTSM, ePRO, eConsent and CTMS. sWith over 500+ clinical trials successfully conducted using its solutions, Clinion is the go-to partner for companies seeking to streamline their clinical trial process and bring new treatments to market faster. For more information on Clinion's new AI-powered medical coding solution, please visit clinion.com. About Clinion Clinion is a global clinical technology company that offers AI-enabled eClinical solutions consisting of EDC, RTSM, CTMS, eCOA and Document Automation that cover the entire clinical trial lifecycle. Clinion is committed to innovating the future of clinical trials through AI/ML and empowering its partners to manage trials more efficiently at lesser costs. For more information, please visit www.clinion.com.

Clinical Trial Technology Trends: The Top 5 Innovations Shaping Clinical Trials in 2023

Discover the top 5 clinical trial technology trends in 2023. From wearables to AI, Digital Patient engagement tools and techniques that are shaping the future of clinical research

Spectrum Healthcare Partners Taps Proscia To Democratize Cancer Diagnosis

Advancing the 150-year-old practice of pathology to improve patient care

bioMérieux Introduces GENE-UP® PRO GENDER ID and GENE-UP® PRO HOP LATENT VIROID (HLVd) Solutions to Enhance Cannabis Cultivation Process Control For Increased Profitability

bioMérieux, a world leader in in vitro diagnostics for 60 years, is pleased to announce the availability of GENE-UP PRO GENDER ID and GENE-UP PRO HOP LATENT VIROID (HLVd) quality control solutions. The addition of these offerings strengthens the company’s comprehensive portfolio of cannabis microbial testing solutions to provide enhanced control of the cannabis cultivation process risk, creating efficiencies and boosting the bottom line from seed to sale. Thanks to rapid detection with a simple workflow, both solutions empower cultivators to act on infected plants to safeguard the health of crops to maximize yield output.

DnaNudge forges strategic partnership with Mylab Discovery Solutions to deliver next-generation point-of-decision diagnostics for diabetic foot infections

MoU signed to develop advanced diagnostic solutions for health conditions including diabetic foot infections – reducing risk of complications and AMR

Optical Brighteners, Plasticizers, and Antioxidants as Polymer Stabilizers

Biopharma PEG To Attend PEGS Boston Summit 2023

Agilent Announces Global Distribution Agreement with Proscia to Accelerate Data-Driven Precision Medicine

Providing a comprehensive digital diagnostic pathology system for enhanced clinical utility

Halteres Associates Launches Halteres Presents Podcast Series

Halteres Associates, a leading bioscience consultancy that provides strategic and tactical services in the areas of diagnostics, medical devices, and life science research to clients of all sizes, today has launched season one of their new podcast series, Halteres Presents. New episodes of season one of Halteres Presents will be released weekly on Apple and Spotify. Season two is already in the works and is set to be released later in 2023. Apple Podcasts Link: https://podcasts.apple.com/us/podcast/halteres-presents/id1675559229 Spotify Link: https://open.spotify.com/show/436uwcDjTxAlOIiVXsGUDJ?si=6f71d5d23e0b4fd4

The IMA Group Announces Leadership Appointment in Clinical Research Division

TARRYTOWN, N.Y. - March 2, 2023 - The IMA Group (IMA), a leading technology-enabled provider of clinical trials and medical and psychological screening and evaluation services, announced today that industry veteran Dana Poff would lead IMA’s Clinical Research Division as Executive Vice President. IMA Clinical Research is a flexible, full-service clinical trial network consisting of geographically diverse clinical trial sites and over 150 satellite sites that conduct site-based, hybrid and decentralized clinical trials. Poff, a high-profile leader in the clinical trial space, brings over 30 years of clinical trial experience to IMA, having held senior level positions overseeing global project management, strategic alliances and clinical operations for ICON, plc.

Creative Enzymes Releases Restriction Enzymes for Molecular Biology Research

Creative Proteomics Enhances Your Project with Cell Surface Proteomics Service

Creative Proteomics Cytokine Boosts Cancer Research with Cancer Cytokines Assay

Pronalyse Announces the Launch of Epitope Mapping Service Utilizing HDX-MS Technology

Fascinating Coordination Complexes and Their Applications

Coordination chemistry investigates the characteristics of coordination compounds formed by the interaction between metal atoms or ions and inorganic, organic ions or molecules, as well as their bonding, structure, reaction, classification, and preparation.

PathGroup Chooses Proscia To Deliver Next Generation Of Cancer Diagnosis For Millions of Patients

Providing faster, higher quality results with enterprise digital pathology

Microbialtec Releases Culture Medium to Support Microbial Research